Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling
the development and supply of better treatments for patients
worldwide, today announced that, at its Special Meeting of
Stockholders (the “Special Meeting”) held earlier today, its
stockholders voted to approve the pending transaction under which
Novo Holdings A/S (“Novo Holdings”) will acquire all outstanding
shares of Catalent for $63.50 per share in cash (the “Merger”).
“Today’s outcome represents an important milestone towards the
closing of this transaction, and we thank our stockholders for
their overwhelming support and their confidence in the future of
Catalent,” said Alessandro Maselli, President and Chief Executive
Officer of Catalent. “Following the closing of the transaction, we
look forward to writing the next chapter for Catalent, benefiting
from Novo Holdings’ expertise and resources as we continue to be a
global leading independent CDMO, developing, manufacturing and
supplying products that help people live better and healthier
lives.”
Based on the preliminary count of the voting results from
today’s Special Meeting, Catalent stockholders voted to approve the
transaction with 99.2% of ballots cast in favor of the proposed
transaction. Catalent anticipates filing the final voting results
for its Special Meeting in a Form 8-K with the Securities and
Exchange Commission, after certification by Catalent’s inspector of
elections.
The transaction is expected to close towards the end of calendar
year 2024, subject to customary closing conditions, including
receipt of required regulatory approvals. The transaction is not
subject to any financing contingency.
About Catalent
Catalent, Inc. is a global leader in enabling pharma, biotech,
and consumer health partners to optimize product development,
launch, and full life-cycle supply for patients around the world.
With broad and deep scale and expertise in development sciences,
delivery technologies, and multi-modality manufacturing, Catalent
is a preferred industry partner for personalized medicines,
consumer health brand extensions, and blockbuster drugs. Catalent
helps accelerate over 1,500 partner programs and launch over 150
new products every year. Its flexible manufacturing platforms at
over 50 global sites supply approximately 70 billion doses of
nearly 8,000 products annually. Catalent’s expert workforce of
nearly 18,000 includes more than 3,000 scientists and technicians.
Headquartered in Somerset, New Jersey, the company generated nearly
$4.3 billion in revenue in its 2023 fiscal year.
Forward-Looking
Statements
This press release and any related oral statements, may include
“forward-looking statements” within the meaning of, and subject to
the safe harbor created by, the federal securities laws, including
statements related to the Merger, including financial estimates and
statements as to the expected timing, completion and effects of the
Merger. These forward-looking statements are based on Catalent’s
current expectations, estimates and projections regarding, among
other things, the expected date of the closing and the potential
benefits thereof, its business and industry, management’s beliefs
and certain assumptions made by Catalent, all of which are subject
to change. Forward-looking statements often contain words such as
“expect,” “anticipate,” “intend,” “aims,” “plan,” “believe,”
“could,” “seek,” “see,” “will,” “may,” “would,” “might,”
“considered,” “potential,” “estimate,” “continue,” “likely,”
“expect,” “target,” “project,” or similar expressions or the
negatives of these words or other comparable terminology that
convey uncertainty of future events or outcomes. By their nature,
forward-looking statements address matters that involve risks and
uncertainties because they relate to events and depend upon future
circumstances that may or may not occur, such as the consummation
of the Merger and the anticipated benefits thereof. These and other
forward-looking statements, as well as any related oral statements,
are not guarantees of future results and are subject to risks,
uncertainties and assumptions that could cause actual results to
differ materially from those expressed in any forward-looking
statements. Important risk factors that may cause such a difference
include, but are not limited to: (i) the completion of the Merger
on anticipated terms and timing, including obtaining antitrust and
other regulatory approvals and clearances, and the satisfaction of
other conditions to the completion of the Merger; (ii) potential
litigation relating to the Merger that could be instituted by or
against Catalent, Novo Holdings or their respective affiliates,
directors or officers, including the effects of any outcomes
related thereto; (iii) the risk that disruptions from the Merger
will harm Catalent’s business, including current plans and
operations; (iv) the ability of Catalent to retain and hire key
personnel; (v) potential adverse reactions or changes to business
or governmental relationships resulting from the announcement or
completion of the Merger; (vi) continued availability of capital
and financing and rating agency actions; (vii) legislative,
regulatory and economic developments affecting Catalent’s business;
(viii) general economic and market developments and conditions;
(ix) certain restrictions during the pendency of the Merger that
may impact Catalent’s ability to pursue certain business
opportunities or strategic transactions; (x) unpredictability and
severity of catastrophic events, including but not limited to acts
of terrorism, pandemics, outbreaks of war or hostilities, as well
as Catalent’s response to any of the aforementioned factors; (xi)
significant transaction costs associated with the Merger; (xii) the
possibility that the Merger may be more expensive to complete than
anticipated, including as a result of unexpected factors or events;
(xiii) the occurrence of any event, change or other circumstance
that could give rise to the termination of the Merger, including in
circumstances requiring Catalent to pay a termination fee or other
expenses; (xiv) competitive responses to the Merger; (xv)
Catalent’s management response to any of the aforementioned
factors; (xvi) the risks and uncertainties pertaining to Catalent’s
business, including those set forth in Catalent’s most recent
Annual Report on Form 10-K and Catalent’s subsequent Quarterly
Reports on Form 10-Q, as such risk factors may be amended,
supplemented or superseded from time to time by other reports filed
or furnished by Catalent with the Securities and Exchange
Commission (“SEC”); and (xvii) the risks and uncertainties that are
described in the definitive proxy statement filed with the SEC on
April 15, 2024 (the “Proxy Statement”). These risks, as well as
other risks associated with the Merger, are more fully discussed in
the Proxy Statement. While the list of factors presented here is,
and the list of factors presented in the Proxy Statement is,
considered representative, no such list should be considered a
complete statement of all potential risks and uncertainties.
Unlisted factors may present significant additional obstacles to
the realization of forward-looking statements. Consequences of
material differences in results as compared with those anticipated
in the forward-looking statements could include, among other
things, actions of governmental authorities, business disruption,
operational problems, financial loss, legal liability to third
parties and similar risks, any of which could have a material
impact on Catalent’s financial condition, results of operations,
credit rating or liquidity. These forward-looking statements speak
only as of the date they are made, and Catalent does not undertake
to and specifically disclaims any obligation to publicly release
the results of any updates or revisions to these forward-looking
statements that may be made to reflect future events or
circumstances after the date of such statements or to reflect the
occurrence of anticipated or unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240529233385/en/
Investor Contact: Paul Surdez +1 (732) 537-6325
investors@catalent.com Media Contact: Laura Hortas +1 (609)
240-7025 media@catalent.com
Catalent (NYSE:CTLT)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Catalent (NYSE:CTLT)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
